Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS

Olaparib, an orally active inhibitor of poly(ADP-ribose)polymerase(PARP), is the drug of choice in the treatment of gBRCA1/2+ metastatic breast cancers. Unfortunately, Olaparib is poorly soluble with low bioavailability and tumor accumulation; nano-delivery could be a good choice to overcome these d...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Roberta Ottria, Alessandro Ravelli, Matteo Miceli, Sara Casati, Marica Orioli, Pierangela Ciuffreda
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2019-03-01
coleção:	Molecules
Assuntos:	Olaparib Olaparib nano-formulation HPLC bioanalysis mass spectrometry sample preparation
Acesso em linha:	http://www.mdpi.com/1420-3049/24/5/989
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!